IRCT20210609051526N1
Not yet recruiting
Phase 3
Efficiency of linagliptin on insulin dosage in type 2 diabetes patients with sever renal failure (randomized clinical trial)
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Type 2 diabetes.
- Sponsor
- Babol University of Medical Sciences
- Enrollment
- 96
- Status
- Not yet recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Type 2 diabetes
- •Severe renal failure (GFR below 30\)
- •Age 80 \- 18 years
- •HbA1C between 7 and 10
Exclusion Criteria
- •Inability to follow the patient
- •Discontinue insulin or linagliptin
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Efficacy of linagliptin on glycemic control in diabetic patients on hemodialysis [Diamond study-1]Diabetic patients on hemodialysisJPRN-UMIN000007635Diamond study group80
Completed
Not Applicable
Safety and efficacy of linagliptin for glycemic control in non-critically ill hospitalized patients with type 2 diabetesJPRN-UMIN000034778Ichinomiyanishi Hospital60
Recruiting
Phase 3
Effect of Linagliptin on Diabetic patients with COVID-19COVID-19.COVID-19, virus identifiedU07.1IRCT20210812052156N1Gonabad University of Medical Sciences70
Active, not recruiting
Not Applicable
Effect of Linagliptin in comparison with Glimepiride as add on to Metformin on the metabolism of diabetic patients after a meal.Diabetes mellitus type 2 on metformin therapyMedDRA version: 14.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Hormonal diseases [C19]EUCTR2012-000179-17-DEikfe GmbH
Completed
Phase 3
Linagliptin Add-on to Insulin Background TherapyDiabetes Mellitus, Type 2NCT02897349Boehringer Ingelheim206